| Abstract |
Objective: To analyze the value of the target management model based on the standardized metabolic disease management center for type 2 diabetes combined with retinopathy. Methods: From July 2020 to January 2022, the Department of Endocrinology received 100 patients with type 2 diabetes and retinopathy, and were randomly divided into 2 groups. The test group adopted the target management method based on the standardized metabolic disease management center, and the control group conducted routine management. Results: For HbA 1 c, fasting glucose and 2h postprandial glucose, at the end of management: the data were (6.74 ± 0.82)%, (6.03 ± 0.39) mmol/L, (8.36 ± 1.25) mmol/L, and lower (9.94 ± 0.48) mmol/L (P <0.05). Regarding total cholesterol, triacylglycerol, LDL cholesterol, and HDL cholesterol, At the end of the management: the data of the test group are (2.07 ± 0.19) mmol/L, (2.17 ± 0.24) mmol/L, (2.52 ± 0.37) mmol/L, (3.14 ± 0.26) mmol/L, Compared with the control group (2.83 ± 0.21) mmol/L, (2.81 ± 0.49) mmol/L, (3.16 ± 0.48) mmol/L, and (3.15 ± 0.25) mmol/L data (P <0.05). Conclusion: Type 2 diabetes combined with retinopathy uses the target management mode based on the standardized metabolic disease management center, with more obvious blood glucose reduction and blood lipid improvement more rapidly.
|